CGMP-specific phosphodiesterase type 5

Results: 69



#Item
21Tadalafil (Adcirca®) Issued by PHA’s Scientific Leadership Council Information is based on the United States Food and Drug Administration drug labeling Last Updated November[removed]WHAT IS TADALAFIL?

Tadalafil (Adcirca®) Issued by PHA’s Scientific Leadership Council Information is based on the United States Food and Drug Administration drug labeling Last Updated November[removed]WHAT IS TADALAFIL?

Add to Reading List

Source URL: www.phassociation.org

Language: English - Date: 2013-12-03 14:16:11
22Sildenafil (Revatio®) Issued by PHA’s Scientific Leadership Council Information is based on the United States Food and Drug Administration drug labeling Last Updated November[removed]WHAT IS SILDENAFIL?

Sildenafil (Revatio®) Issued by PHA’s Scientific Leadership Council Information is based on the United States Food and Drug Administration drug labeling Last Updated November[removed]WHAT IS SILDENAFIL?

Add to Reading List

Source URL: www.phassociation.org

Language: English - Date: 2013-12-03 14:16:11
23The score is 26 to 0. There are actually 41 drugs marketed for male sexual dysfunction if you include generics. Even the Score only counts those drugs that have been uniquely approved as new drugs by the FDA and marketed

The score is 26 to 0. There are actually 41 drugs marketed for male sexual dysfunction if you include generics. Even the Score only counts those drugs that have been uniquely approved as new drugs by the FDA and marketed

Add to Reading List

Source URL: eventhescore.org

Language: English - Date: 2014-10-01 17:52:58
24Microsoft Word - CMDh-PhVWP-002-2009_Rev0_Feb09

Microsoft Word - CMDh-PhVWP-002-2009_Rev0_Feb09

Add to Reading List

Source URL: www.hma.eu

Language: English - Date: 2009-10-30 07:45:33
25Management of ED (Erectile Dysfunction) Expectations: It will NEVER be as good as it was when you were young. The BEST that can be hoped for is that it will be almost as good as it was before you lost the ability to achi

Management of ED (Erectile Dysfunction) Expectations: It will NEVER be as good as it was when you were young. The BEST that can be hoped for is that it will be almost as good as it was before you lost the ability to achi

Add to Reading List

Source URL: www.nellis.af.mil

Language: English - Date: 2014-07-11 17:41:12
26HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use REVATIO safely and effectively. See full prescribing information for REVATIO.  •

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use REVATIO safely and effectively. See full prescribing information for REVATIO. •

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2010-11-26 15:04:41
27EMA[removed]EMEA/H/C[removed]EPAR summary for the public  Spedra

EMA[removed]EMEA/H/C[removed]EPAR summary for the public Spedra

Add to Reading List

Source URL: www.ema.europa.eu

Language: English - Date: 2013-07-21 06:43:29
2810  WKU Scholar | Academic Year[removed] Sharron Francis:

10 WKU Scholar | Academic Year[removed] Sharron Francis:

Add to Reading List

Source URL: www.wku.edu

Language: English - Date: 2012-10-29 16:12:27
29Phosphodiesterase 4D is required for ␤2 adrenoceptor subtype-specific signaling in cardiac myocytes Yang Xiang*†, Fabio Naro†‡§, Maria Zoudilova‡, S.-L. Catherine Jin‡, Marco Conti‡¶, and Brian Kobilka*¶

Phosphodiesterase 4D is required for ␤2 adrenoceptor subtype-specific signaling in cardiac myocytes Yang Xiang*†, Fabio Naro†‡§, Maria Zoudilova‡, S.-L. Catherine Jin‡, Marco Conti‡¶, and Brian Kobilka*¶

Add to Reading List

Source URL: med.stanford.edu

Language: English - Date: 2009-12-04 19:10:48
30Phosphodiesterase Type 5 Inhibition with Tadalafil CHanges Outcomes in Heart Failure (PITCH-HF) CCC Principal Investigator: Marc J. Semigran, MD Massachusetts General Hospital, New England Research Institutes, NHLBI  Bac

Phosphodiesterase Type 5 Inhibition with Tadalafil CHanges Outcomes in Heart Failure (PITCH-HF) CCC Principal Investigator: Marc J. Semigran, MD Massachusetts General Hospital, New England Research Institutes, NHLBI Bac

Add to Reading List

Source URL: www.hfsa.org

Language: English - Date: 2013-10-12 15:48:10